Clinical trials: Liver Cell Carcinoma Non-resectable
Liver Cancer
A Non-Randomized Study of Internal Radiation Therapy to the Liver in Patients With Primary Liver Cancer for Whom Surgery is Not Possible.
Surgical resection of the affected liver offers the best chance for disease-free survival in patients with Hepatoma (HCC). Unfortunately, most hepatoma patients present with disease which is multi-focal and thus not resectable.
- Trial name
- NCT00152087
- Testing
- Brachytherapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- St. Joseph's Hospital, Florida
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
The main purpose of this study is to evaluate the safety of ramucirumab plus MEDI4736 in participants with locally advanced and unresectable or metastatic gastrointestinal or thoracic malignancies including gastric or…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
- Trial name
- NCT02572687
- Testing
- Ramucirumab, MEDI4736
- Where
- 28 sites in United States, France and 6 more
- Volunteers
- 85 people
- Sponsor
- Eli Lilly and Company
Hepatocellular Carcinoma
The Efficacy of Sequential RT After Triple Therapy for uHCC
Triple therapy of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies has demonstrated excellent efficacy in unresectable hepatocellular carcinoma (uHCC).
- Trial name
- NCT07052448
- Testing
- sequential radiotherapy after the combination of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Fujian Provincial Hospital
Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life.
- Conditions
- Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8
- Trial name
- NCT06265285
- Testing
- Home Health Encounter, Nivolumab, Patient Monitoring
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Unresectable Hepatocellular Carcinoma
HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC
Drug-eluting Bead-Transarterial chemoembolization (D-TACE) is the most widely used palliative treatment for hepatocellular carcinoma (HCC) patients.
- Trial name
- NCT05582278
- Testing
- D-TACE, HAIC, Lenvatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Wen Li
Carcinoma, Hepatocellular
A Study of PTX-9908 Injection for Non-resectable HCC With TACE
This is a multicenter, Phase I/II study in patients with non-resectable hepatocellular carcinoma following TACE treatment. Phase I (Open-label dose escalation) This study will be an open-label study with an Accelerated Phase and…
- Trial name
- NCT03812874
- Testing
- PTX-9908 Injection
- Where
- Taiwan
- Sponsor
- TCM Biotech International Corp.
Hepatocellular Carcinoma Resectable
Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer
This is a single-center, prospective, non-randomized, open-label, phase II clinical trial aiming to evaluate the efficacy and feasibility of using patient-derived tumor organoid drug sensitivity testing (ODST) to guide…
- Trial name
- NCT07363356
- Testing
- Organoid Drug Sensitivity Testing-Guided Therapy
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Unresectable Hepatocellular Carcinoma
Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrade arginine. ADI has been formulated with polyethylene glycol and has been used to treat patients that have cancers…
- Trial name
- TACE (NCT02006030)
- Testing
- ADI-PEG 20, Transarterial chemoembolization
- Where
- 4 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- Polaris Group
Unresectable Hepatocellular Carcinoma, Hepatocellular Carcinoma by BCLC Stage
A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)
This study was designed to evaluate the effectiveness and safety of hepatic arterial infusion chemotherapy combined with Bevacizumab and Sintilimab (Triplet-combined Therapy) for Unresectable A-staged Hepatocellular Carcinoma in…
- Trial name
- NCT05214339
- Testing
- Hepatic Arterial Infusion(mFOLFOX7) combined with Bevacizumab and Sintilimab
- Where
- 5 sites in China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib…
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
- Trial name
- STELLAR-002 (NCT05176483)
- Testing
- Zanzalintinib, Nivolumab, Ipilimumab
- Where
- 122 sites in United States, Australia and 11 more
- Volunteers
- 1,394 people
- Sponsor
- Exelixis
Hepatocellular Carcinoma
Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma
The investigators design a phase IIB clinical study to explore the efficacy and safety of Donafenib combined with Sintilimab and HAIC in the first-line treatment of unresectable hepatocellular carcinoma
- Trial name
- NCT05166772
- Testing
- Donafenib, Sintilimab, HAIC
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colorectal Cancer Metastatic
Living Donor Liver Transplant for Unresectable Colorectal Liver Metastases
The goal of this study is to create a data registry to capture clinical, pathologic, and molecular data/outcomes for patients with metastatic colorectal cancer who undergo live donor liver transplantation.
- Trial name
- NCT05248581
- Testing
- Liver transplantation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Rochester
Carcinoma, Hepatocellular
A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care
Approximately 18-45 patients with Hepatocellular Carcinoma (HCC) will be treated with DENSPM at approximately 5 centers in the United States.
- Trial name
- NCT00081900
- Testing
- DENSPM )
- Where
- 8 sites in United States
- Volunteers
- 38 people
- Sponsor
- Genzyme, a Sanofi Company
Hepatocellular Carcinoma Non-resectable
BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)
The primary objective of the study is to confirm safety and technical success of BioPearl™ microspheres loaded with Doxorubicin in the treatment of unresectable hepatocellular carcinoma (HCC).
- Trial name
- BIOPEARL-ONE (NCT05911633)
- Testing
- BioPearl™
- Where
- 10 sites in Belgium, France and 2 more
- Volunteers
- 50 people
- Sponsor
- Terumo Europe N.V.
Primary Liver Cancer, Non-Resectable Hepatocellular Carcinoma
MRI-guided Holmium-166 Radioembolization
To investigate the safety and feasibility of a personalized Ho-166-PLLA-MS TARE approach by using MRI guidance in inoperable patients with HCC.
- Trial name
- EMERITUS-2 (NCT05609448)
- Testing
- MRI-guided radioembolization
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Radboud University Medical Center
Cancer
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499733
- Testing
- cyclophosphamide, Cryoablation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)
A study to evaluate the efficacy and safety of icaritin versus huachansu in the first-line treatment of unresectable hepatocellular carcinoma with poor conditions and biomarker enrichment.
- Trial name
- BESTPOP (NCT05594927)
- Testing
- Icaritin, Huachansu
- Where
- 3 sites in China
- Volunteers
- 261 people
- Sponsor
- Beijing Shenogen Biomedical Co., Ltd
Hepatocellular Carcinoma
LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Advanced HCC represents a high unmet medical need with a poor prognosis and few therapeutic options. Patients who present with HCC beyond the currently accepted Milan criteria are not eligible to be listed for liver…
- Trial name
- HCC (NCT00877071)
- Testing
- LC Bead loaded with doxorubicin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Pittsburgh
Unresectable Hepatocellular Carcinoma
HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure
The efficacy and safety of HAIC combined with tyrosine kinase inhibitor and immunotherapy have been proved by the clinical research.
- Trial name
- NCT05135364
- Testing
- Camrelizumab, HAIC, TKI
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Yue Han